BAK1 and Fabry disease: Daily treatment with levodopa (15 mM; Supplementary Figure S-1C & 6E), levodopa:carbidopa (15 mM:3.75 mM; Supplementary Figure S-1 D & 6F), or levodopa:BAK (15 mM in 0.1%; Supplementary Figure S-1 E & 6G) drops over four weeks induced no observable changes in retinal structure or architecture (Supplementary Figure S-1), or observable signs of apoptosis (Supplementary Figure S-2), relative to that seen in FD or age-matched untreated control eyes (Supplementary Figures S-1 A & S-2 C).